RxDoctor Payments Data

Michael Schmidt, MD

Family Medicine · Thomasville, GANPI 1669572970

Payments from drug & device makers

$3,021in general payments, 2019–2025

Across 143 payments — averaging $21.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$637
  • Biotronik NRO, Inc.$226
  • GSK$222
  • Bayer$210
  • AstraZeneca$202
  • Abbott$173
  • plus $1K from 24 others

What the payments were for

  • Travel & lodging$1736%
  • Food & beverage$2,84894%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,021 in reported general payments places this provider in the 75th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$16,290
Medicare patients
244
Services billed
1,019

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide156$185,519
TrulicityDulaglutide136$131,228
JardianceEmpagliflozin94$100,990
JanuviaSitagliptin Phosphate41$57,766
FarxigaDapagliflozin Propanediol39$56,354
MounjaroTirzepatide36$55,025
EliquisApixaban52$51,541
XareltoRivaroxaban29$38,845
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$34,484
LinzessLinaclotide17$17,977
MyrbetriqMirabegron17$14,201
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen343$7,962
SymbicortBudesonide/Formoterol Fumarate18$7,082
ShingrixVaricella-Zoster Ge/As01b/Pf24$5,273
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$4,974

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humulin 70-30$144$187,789190 claims
Novo NordiskOzempic$637$185,519156 claims
Boehringer IngelheimJardiance$54$100,99094 claims
AstraZenecaFarxiga, Symbicort$202$63,43657 claims
MerckJanuvia$66$57,76641 claims
PfizerEliquis$67$51,54152 claims
GSKTrelegy Ellipta, Shingrix$222$39,75761 claims
Johnson & JohnsonXarelto$86$38,84529 claims
AbbVieLinzess$11$17,97717 claims
Astellas Pharma US IncMyrbetriq$19$14,20117 claims
Sanofi-aventis U.S. LLCLantus$19$1,66314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Thomasville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →